Health screening is the systematic use of a test, examination, questionnaire or other assessment to identify apparently healthy people who have a higher chance of having a particular disease or developing it, so that they can be offered further assessment, treatment, monitoring or preventive advice. Screening is fundamentally different from investigating symptoms. Diagnostic testing is normally performed because a person has symptoms, signs or another clinical reason for suspecting disease, whereas screening targets people who may feel completely well. The purpose is to identify important conditions at an earlier stage, when intervention may be more effective or when treatment can prevent disease from becoming clinically significant.
A screening test is not usually intended to provide a definitive diagnosis. A positive or higher-risk screening result generally means that further diagnostic testing is needed to determine whether the disease or abnormality is actually present. Conversely, a negative screening result means that the person's estimated risk is lower at that particular point in time, not that disease is impossible or that the person will never develop it.
This distinction is essential because screening tests deliberately operate as risk-identification tools rather than perfect diagnostic instruments. The interpretation of a result therefore depends on the sensitivity and specificity of the test, the prevalence of the condition in the population being screened and the person's underlying risk.
Screening programmes can target different stages of life and different diseases. Examples include newborn screening, cervical screening, breast screening and bowel-cancer screening, while other programmes identify cardiovascular or metabolic risk. In England, the NHS provides population screening programmes according to evidence-based recommendations, with eligibility determined by factors such as age, sex or anatomy and the characteristics of the disease. The UK National Screening Committee advises the NHS across the four UK countries about which screening programmes should be offered. Screening therefore differs from a general "check everything" health examination because programmes are designed around particular diseases, populations, tests and evidence.
The scientific basis of screening depends on the natural history of the condition. Screening is most useful when a detectable stage exists before serious clinical consequences occur and when intervention during that stage improves outcomes. There also needs to be an acceptable test with sufficient accuracy, a population in which the disease is sufficiently relevant to justify screening and an effective pathway for diagnostic confirmation and treatment. If finding a condition earlier does not improve outcomes, screening may provide little benefit despite being technically capable of detecting disease. This is why the existence of a test alone is not enough to justify a population screening programme.
Screening produces several possible statistical outcomes. A true positive occurs when screening identifies a person who genuinely has the target condition, while a true negative occurs when it correctly identifies someone without it. A false positive occurs when a screening result is abnormal even though the person does not have the target disease, potentially leading to anxiety or invasive diagnostic procedures. A false negative occurs when screening fails to identify an existing condition. Sensitivity describes how well a test detects people who have the condition, while specificity describes how well it correctly identifies people who do not. Positive and negative predictive values depend additionally on the underlying prevalence and risk of disease in the population tested.
Screening can therefore have benefits as well as limitations. Benefits include earlier detection, prevention of disease progression, access to earlier treatment and, for some conditions, prevention of disease altogether. Limitations include false-positive and false-negative results, overdiagnosis, unnecessary investigations, psychological effects, inconvenience and the possibility that people misunderstand a negative result as a permanent guarantee of health. Screening programmes must also consider opportunity costs: resources devoted to screening are resources that cannot simultaneously be used for other healthcare services. Good screening policy therefore evaluates overall health outcomes rather than assuming that more testing is automatically better.
Screening is closely related to health checks but the terms are not synonymous. A health check may combine measurements, medical history and risk assessment across several conditions, whereas a screening programme normally targets a defined disease or group of diseases using specified eligibility criteria and follow-up pathways. For example, the NHS Health Check in England assesses cardiovascular risk and associated factors in eligible adults rather than functioning as a universal diagnostic examination for every possible disease. The check can include measurements such as blood pressure, cholesterol, weight and lifestyle information and can lead to advice or further assessment.
The practical meaning of a screening result is therefore conditional and time-specific. A normal result indicates that the person is at relatively low risk according to the screening test at that point, whereas an abnormal result identifies a need for further evaluation rather than establishing a diagnosis. Screening should be integrated with accessible diagnostic services and effective treatment because early detection has limited value if people cannot obtain appropriate follow-up. The most useful screening programmes are consequently complete pathways rather than isolated tests: eligible people are invited, the test is performed accurately, results are communicated, abnormal findings are investigated and appropriate treatment or surveillance is provided.
